Strides Pharma Receives USFDA Form 483 With Three Observations for Alathur Facility
Strides Pharma Science Ltd 路 Others (Uncategorized) 路 12 Sept 2026, 3:17 am
Strides Pharma Receives USFDA Form 483 With Three Observations for Alathur Facility The USFDA concluded a routine cGMP inspection at Strides Pharma Science's formulations facility in Alathur, Chennai, conducted from 2nd Sep'26 to 11th Sep'26. Upon completion of the inspection, the regulator issued a Form 483 containing three observations. The company confirmed it will submit its response to the USFDA within the stipulated timeframe.
Original exchange filing (PDF)
More announcements from Strides Pharma Science Ltd
- Transcript of Earnings Call pertaining of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 路 02 Nov 2026
- Audio Recording of Earnings Call pertaining to unaudited Financial Results for the quarter and half year ended September 30, 2026 路 30 Oct 2026
- Appointment of Mr. Biren Gabhawala (DIN:03091772) as a Non-Executive Independent Director of the Company with effect from November 1, 2026. 路 30 Oct 2026
- Allotment of Equity shares pursuant to exercise of Stock Options. 路 30 Oct 2026
- Earnings presentation for the quarter and half year ended September 30, 2026. 路 30 Oct 2026
- Strides Delivers Strong Performance with Q2FY27 Revenue at Rs. 14.297m, Grew 17% YoY. Ex-US Markets Up 31% YoY; EBITDA Up 8% YoY to Rs. 2,509m, Crossing Rs. 2,500m in a Quarter for the First Time. 路 30 Oct 2026
- Financial Results for the quarter and half year ended Sept 30, 2026 路 30 Oct 2026
- Strides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 30 Oct 2026
